AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index slipping due to weak trade data from China, highlighting concerns over global economic recovery. In this ...

Wealthfront Advisers LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange ...

We recently published a list of 10 Best European Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best ...

(Alliance News) - AstraZeneca PLC on Monday announced an acquisition, a license agreement, regulatory approval in Europe for cancer drug Imfinzi, and a further positive product update in a busy start ...

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...